| TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia |
|
Molecular Medicine |
Aplastic Anemia |
| Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy |
|
Mediterranean Journal of Hematology and Infectious Diseases |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Observational and Genetic Association of Myelodysplastic Syndromes (MDS) and Autoimmune Diseases in Adults |
|
Mediators of Inflammation |
Myelodysplastic Syndromes (MDS) |
| Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
|
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study |
|
Leukemia Research |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
